Prospera Private Wealth LLC Makes New Investment in Insulet Co. (NASDAQ:PODD)

Prospera Private Wealth LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 644 shares of the medical instruments supplier’s stock, valued at approximately $150,000.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. lifted its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Insulet in the second quarter valued at $32,000. Venturi Wealth Management LLC lifted its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the period. Finally, CVA Family Office LLC lifted its holdings in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the period.

Insulet Stock Up 1.8 %

PODD opened at $266.58 on Thursday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The business has a 50-day moving average of $240.09 and a 200-day moving average of $209.62. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $18.70 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 3.98 and a beta of 1.22.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Canaccord Genuity Group boosted their target price on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.